Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Serum Institute to...

    Serum Institute to unveil thermostable rotavirus vaccine Rotasiil in 9 countries next year

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-08-16T09:26:26+05:30  |  Updated On 16 Aug 2019 9:26 AM IST
    Serum Institute to unveil thermostable rotavirus vaccine Rotasiil in 9 countries next year

    Rotasiil remains stable for up to 30 months at a temperature of 25 degrees Celsius, Serum Institute said in a statement. This helps reduce vaccine wastage as well as the cost of logistics and maintenance of the vaccine during storage and increases accessibility, it added.


    New Delhi: Vaccines major Serum Institute of India is looking to launch its thermostable rotavirus vaccine Rotasiil in nine more countries next year.


    Rotasiil remains stable for up to 30 months at a temperature of 25 degrees Celsius, Serum Institute said in a statement. This helps reduce vaccine wastage as well as the cost of logistics and maintenance of the vaccine during storage and increases accessibility, it added.


    "The vaccine is expected to launch in the Philippines, Niger, Kazakhstan, Namibia, Bahrain, Russia, Thailand, Uganda and Uzbekistan within the next year," Serum Institute CEO Adar C Poonawalla told.


    Rotasiil will help reduce misapplication, wastefulness, cost for logistics, increase availability and therefore, help millions more lead a healthier life, he added.


    Read Also: UK hopes to prevent 100000 cancer cases; HPV vaccines will be rolled out to boys


    "Providing a healthy life to their children is the dream of every parent, and the term stabilizing of the Rotasiil vaccine is one step towards that direction," Poonawalla said.


    The vaccine has so far been supplied to Saudi Arabia, Kyrgyzstan, Turkmenistan, Albania, and D.R. Congo, apart from India, Serum Institute said.


    The Government of India is already using Rotasiil in the universal immunization program in its bid to improve public healthcare across the nation.


    Founded in 1966 by Cyrus Poonawalla, the Serum Institute of India Pvt Ltd is the world's largest vaccine manufactured by a number of doses produced and sold globally with more than 1.5 billion doses per annum.


    Vaccines manufactured by the company are being used in around 170 countries across the globe for national immunization programs.


    Read Also: Philippines weighs re-use of Sanofi controversial dengue vaccine Dengvaxia

    Adar C PoonawallachinaCyrus Poonawallaglobal launchgovt of indiaHealthcarelogisticspharmapharma newspharma news indiaROTASIILrotavirus vaccineserumSerum InstituteThermostablevaccine wastage
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok